Cargando...
Brexanolone for the treatment of patients with postpartum depression
On March 19, 2019, the United States Food and Drug Administration (FDA) approved Zulresso (brexanolone) for intravenous use for the treatment of postpartum depression (PPD) in adult women. The decision was based on three recent clinical trials following an FDA priority review and breakthrough therap...
Gardado en:
| Publicado en: | Drugs Today (Barc) |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8033597/ https://ncbi.nlm.nih.gov/pubmed/31584571 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1358/dot.2019.55.9.3040864 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|